

OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Executive Officer

Nantes, France – October 7, 2022, 6:00 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Dr. Nicolas Poirier as new Chief Executive Officer, effective immediately. This appointment follows the decision of the Board of Directors to terminate the mandate of Alexis Vandier.

Throughout his career, Dr. Nicolas Poirier has demonstrated both his expertise as an international scientific leader, pioneering the discovery and development of innovative immunotherapies, and in-depth knowledge of the biotech sector through various strategic leadership roles. He has been instrumental in the development of OSE Immunotherapeutics, notably as the initiator of 5 programs in the Company's portfolio that are now in clinical stage. He also played a major role in the signature of 4 strategic pharmaceutical partnerships for OSE Immunotherapeutics.

"Since the creation of OSE Immunotherapeutics in 2016, Nicolas' world-class scientific expertise, along with his well-recognized human and leadership skills have been vital in the development of the Company, guiding the advancement from the identification of new therapeutic targets into the development of new drugs for severe diseases with a strong medical need. He has been essential in building our diversified portfolio of first-in-class products. He has been able to convince leading scientific experts and our pharmaceutical partners of the value of our innovations. Nicolas' leadership will allow OSE Immunotherapeutics to accelerate the implementation of our strategic priorities and to achieve new growth milestones," said Dominique Costantini, President of OSE Immunotherapeutics.

Nicolas Poirier, Chief Executive Officer and Chief Scientific Officer of OSE Immunotherapeutics, commented: *"I am very honored to be appointed CEO and would like to thank the Board of Directors for placing their trust in me at a key stage of the Company's development. I am proud of the work accomplished by our teams, all of whom are focused on advancing our late-stage clinical development programs and high-potential research platforms. I am deeply convinced that OSE Immunotherapeutics' assets will be able to transform the care of patients suffering from cancer and chronic inflammatory diseases."*

Nicolas Poirier holds a PhD in Immunology (European Center for Transplantation and Immunotherapy Sciences, Nantes), a double master's degree in Biotechnology from the University of Nantes and in Pharmacology from the University of Louis Pasteur in Strasbourg and a certification in Global Management from INSEAD.

Nicolas Poirier has been Chief Scientific Director and member of the management team of OSE Immunotherapeutics since 2016. He started his career at Tci Pharma in 2009 as a researcher, became Project Manager at Effimune in 2012, then Director of R&D programs in 2014. In addition, Nicolas Poirier is an active member of the Strategic and Scientific Advisory Committee (COSSF) of the French biomedical industry association (MabDesign). Over the past fifteen years, he has authored more than 50 peer-reviewed international scientific publications and holds over 40 issued patents in the field of

immunotherapy. Nicolas Poirier and his team have obtained more than 45 million euros in French and European public funding to co-finance OSE Immunotherapeutics' research and development programs.

ABOUT OSE Immunotherapeutics

OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation. The Company's current well-balanced first-in-class clinical pipeline includes:

- **Tedopi®** (T-cell specific immunotherapy, off-the-shelf, neoepitope-based): the Company's most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi® in combination are ongoing in solid tumors.
- **OSE-279** (anti-PD1): advanced preclinical stage.
- **OSE-127/S95011** (humanized monoclonal antibody antagonist of IL-7 receptor) developed in partnership with Servier; ongoing Phase 2 in ulcerative colitis (sponsor OSE Immunotherapeutics) and ongoing Phase 2a in Sjögren's syndrome (sponsor Servier).
- **VEL-101/FR104** (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); Phase 1 ongoing in the US (sponsor Veloxis Pharmaceuticals, Inc.).
- **BI 765063** (anti-SIRPα monoclonal antibody on CD47/SIRPα pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results of BI 765063 in monotherapy and in combination, in particular with anti-PD-1 antibody ezabemlimab; BI sponsored international Phase 1b ongoing clinical trial in combination with ezabemlimab alone or with other drugs in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC).

OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics:

- **BiCKI® platform** focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. The most advanced BiCKI® candidate is targeting anti-PD1xIL-7.
- **Myeloid platform** focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). **OSE-230** (ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Additional information about OSE Immunotherapeutics assets is available on the Company's website: www.ose-immuno.com

Click and follow us on Twitter and LinkedIn



Contacts

OSE Immunotherapeutics

Sylvie Détry
sylvie.detry@ose-immuno.com
+33 153 198 757

French Media: FP2COM

Florence Portejoie
fportejoie@fp2com.fr
+33 607 768 283

International Media: MEDISTRAVA Consulting

Sylvie Berrebi / David Dible / Eleanor Perkin
OSEImmuno@medistrava.com
+44 (0) 203 928 6900

Investor Relations

Thomas Guillot
thomas.guillot@ose-immuno.com
+33 607 380 431

Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2022, including the annual financial report for the fiscal year 2021, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.